Psilocybin: Characterization of the Metastable Zone Width (MSZW), Control of Anhydrous Polymorphs, and Particle Size Distribution (PSD)
The Food and Drug Administration for clinical trials involving major depressive disorder and treatment-resistant depression granted psilocybin a “breakthrough therapy” status. The direct phosphorylation of psilocin to psilocybin that uses a fast crystallization associated with a kinetically controlled process resulted in a smaller particle size distribution.
The quest for an ideal crystallization process in the past has been enigmatic but has become a very commonly used separation process in many different industries, including materials and pharmaceutical industries. This article aims to investigate the applicability of a crystal engineering technique that improves the physicochemical properties of psilocybin API.
Read the below article to find out more.View Resource
Almac API, Chemical Development, Analytical & Solid State Services
Almac Sciences provides integrated services from development to commercial scale of advanced intermediates and Active Pharmaceutical Ingredients (API).
We provide a range of services for small molecules (including highly potent) and peptides. We have a proven track record of saving time and cost through the integration of our services and application of innovative biocatalysis and technology solutions.
We offer a full suite of analytical testing for a range of different product types including small molecules, peptides, biologics, conjugates, potent and controlled substances.
Our vast pool of scientific knowledge can help to overcome the analytical challenges that typically arise during drug development.